SCHEMBL13764284

SCHEMBL13764284

CCOC(=O)Cc1cn2ccnc(SC)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
ALDH1A1 P00352 6/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 7/20 0.38
GAA P10253 1/20 0.37
POLB P06746 2/20 0.36
FPR1 P21462 2/20 0.36
CYP1A2 P05177 1/20 0.36
THRB P10828 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HPGD P15428 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595996 0.84 KDM4E (0.43) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL18189892 0.81 KDM4E (0.54) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL14507509 0.76 KDM4E (0.54) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL20596629 0.74 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL7982689 0.73 ALDH1A1 (0.46) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL7981086 0.73 KDM4E (0.44) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL7986876 0.73 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2MAPTKDM4EGAA
SCHEMBL15069034 0.72 MEN1 (0.42) MEN1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL20596062 0.72 GRIA1 (0.45) MEN1KMT2AALDH1A1KDM4E
SCHEMBL18189768 0.72 ROCK1 (0.32) ALDH1A1KDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557104-B2 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-07-07 US disclosed
US-7557104-B2 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-07-07 US disclosed
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2008-01-31 US disclosed
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027063-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS CHEK1, CHEK2, CDKN1A MEN1 2085/4885KMT2A 883/4885ALDH1A1 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.